Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed

The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cel...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2013-03, Vol.339 (6127), p.1563-1566
Main Author: McLeod, Howard L.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biology
Biomarkers, Pharmacological
Biomarkers, Tumor - genetics
Breast cancer
Cancer
Clinical trials
DNA
Dosing
Drug Design
Drugs
Female
Genetic Markers
Genetic mutation
Genome, Human
Genomics
Germ-Line Mutation
Humans
Molecular Targeted Therapy
Mutations
Neoplasms - drug therapy
Neoplasms - genetics
Oncology
Patients
Pharmaceutical sciences
Pharmacogenetics
REVIEWS
Sequencing
Side effects
Somatic mutation
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43
cites cdi_FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43
container_end_page 1566
container_issue 6127
container_start_page 1563
container_title Science (American Association for the Advancement of Science)
container_volume 339
creator McLeod, Howard L.
description The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs—knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.
doi_str_mv 10.1126/science.1234139
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3900028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41942082</jstor_id><sourcerecordid>41942082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43</originalsourceid><addsrcrecordid>eNqFkUtLxDAUhYMoOj7WrpSCGxd2zPvhQtAyPmBQF7oOaZpqh06jSSv4743MOKgbV0k43z3ckwPAPoJjhDA_jbZxnXVjhAlFRK2BEYKK5QpDsg5GEBKeSyjYFtiOcQZh0hTZBFuYMJKufASKwqT5kD28mDA31j-7zs8bG8-yiQntR_YQ0jO6k-xy6LPCf7G9q7JJXfvQZ3fOVa7aBRu1aaPbW5474Olq8ljc5NP769viYppbJlif1yU0UgrFWYkrwZUkllPJEWW2NsJQJCSGTAmOmKypLQ1XyhBccoFLqWpKdsD5wvd1KOeusq7rg2n1a2jmJnxobxr9W-maF_3s3zVRKTqWyeB4aRD82-Bir1M269rWdM4PUSMJJYICEvI_yjiXlCAFE3r0B535IXTpJzQiGFGaMJao0wVlg48xuHq1N4L6q0u97FIvu0wThz_jrvjv8hJwsABmsfdhpVOkKIYSk0-djqMU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1321444315</pqid></control><display><type>article</type><title>Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed</title><source>American Association for the Advancement of Science</source><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Alma/SFX Local Collection</source><creator>McLeod, Howard L.</creator><creatorcontrib>McLeod, Howard L.</creatorcontrib><description>The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs—knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.</description><identifier>ISSN: 0036-8075</identifier><identifier>EISSN: 1095-9203</identifier><identifier>DOI: 10.1126/science.1234139</identifier><identifier>PMID: 23539596</identifier><identifier>CODEN: SCIEAS</identifier><language>eng</language><publisher>United States: American Association for the Advancement of Science</publisher><subject>Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biology ; Biomarkers, Pharmacological ; Biomarkers, Tumor - genetics ; Breast cancer ; Cancer ; Clinical trials ; DNA ; Dosing ; Drug Design ; Drugs ; Female ; Genetic Markers ; Genetic mutation ; Genome, Human ; Genomics ; Germ-Line Mutation ; Humans ; Molecular Targeted Therapy ; Mutations ; Neoplasms - drug therapy ; Neoplasms - genetics ; Oncology ; Patients ; Pharmaceutical sciences ; Pharmacogenetics ; REVIEWS ; Sequencing ; Side effects ; Somatic mutation ; Tumors</subject><ispartof>Science (American Association for the Advancement of Science), 2013-03, Vol.339 (6127), p.1563-1566</ispartof><rights>Copyright © 2013 American Association for the Advancement of Science</rights><rights>Copyright © 2013, American Association for the Advancement of Science</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43</citedby><cites>FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41942082$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41942082$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,780,784,885,2884,2885,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23539596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McLeod, Howard L.</creatorcontrib><title>Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed</title><title>Science (American Association for the Advancement of Science)</title><addtitle>Science</addtitle><description>The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs—knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.</description><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biology</subject><subject>Biomarkers, Pharmacological</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Clinical trials</subject><subject>DNA</subject><subject>Dosing</subject><subject>Drug Design</subject><subject>Drugs</subject><subject>Female</subject><subject>Genetic Markers</subject><subject>Genetic mutation</subject><subject>Genome, Human</subject><subject>Genomics</subject><subject>Germ-Line Mutation</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Mutations</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacogenetics</subject><subject>REVIEWS</subject><subject>Sequencing</subject><subject>Side effects</subject><subject>Somatic mutation</subject><subject>Tumors</subject><issn>0036-8075</issn><issn>1095-9203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkUtLxDAUhYMoOj7WrpSCGxd2zPvhQtAyPmBQF7oOaZpqh06jSSv4743MOKgbV0k43z3ckwPAPoJjhDA_jbZxnXVjhAlFRK2BEYKK5QpDsg5GEBKeSyjYFtiOcQZh0hTZBFuYMJKufASKwqT5kD28mDA31j-7zs8bG8-yiQntR_YQ0jO6k-xy6LPCf7G9q7JJXfvQZ3fOVa7aBRu1aaPbW5474Olq8ljc5NP769viYppbJlif1yU0UgrFWYkrwZUkllPJEWW2NsJQJCSGTAmOmKypLQ1XyhBccoFLqWpKdsD5wvd1KOeusq7rg2n1a2jmJnxobxr9W-maF_3s3zVRKTqWyeB4aRD82-Bir1M269rWdM4PUSMJJYICEvI_yjiXlCAFE3r0B535IXTpJzQiGFGaMJao0wVlg48xuHq1N4L6q0u97FIvu0wThz_jrvjv8hJwsABmsfdhpVOkKIYSk0-djqMU</recordid><startdate>20130329</startdate><enddate>20130329</enddate><creator>McLeod, Howard L.</creator><general>American Association for the Advancement of Science</general><general>The American Association for the Advancement of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QQ</scope><scope>7QR</scope><scope>7SC</scope><scope>7SE</scope><scope>7SN</scope><scope>7SP</scope><scope>7SR</scope><scope>7SS</scope><scope>7T7</scope><scope>7TA</scope><scope>7TB</scope><scope>7TK</scope><scope>7TM</scope><scope>7U5</scope><scope>7U9</scope><scope>8BQ</scope><scope>8FD</scope><scope>C1K</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>20130329</creationdate><title>Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed</title><author>McLeod, Howard L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biology</topic><topic>Biomarkers, Pharmacological</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Clinical trials</topic><topic>DNA</topic><topic>Dosing</topic><topic>Drug Design</topic><topic>Drugs</topic><topic>Female</topic><topic>Genetic Markers</topic><topic>Genetic mutation</topic><topic>Genome, Human</topic><topic>Genomics</topic><topic>Germ-Line Mutation</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Mutations</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacogenetics</topic><topic>REVIEWS</topic><topic>Sequencing</topic><topic>Side effects</topic><topic>Somatic mutation</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McLeod, Howard L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Ecology Abstracts</collection><collection>Electronics &amp; Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Materials Business File</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts – Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Science (American Association for the Advancement of Science)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McLeod, Howard L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed</atitle><jtitle>Science (American Association for the Advancement of Science)</jtitle><addtitle>Science</addtitle><date>2013-03-29</date><risdate>2013</risdate><volume>339</volume><issue>6127</issue><spage>1563</spage><epage>1566</epage><pages>1563-1566</pages><issn>0036-8075</issn><eissn>1095-9203</eissn><coden>SCIEAS</coden><abstract>The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs—knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.</abstract><cop>United States</cop><pub>American Association for the Advancement of Science</pub><pmid>23539596</pmid><doi>10.1126/science.1234139</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0036-8075
ispartof Science (American Association for the Advancement of Science), 2013-03, Vol.339 (6127), p.1563-1566
issn 0036-8075
1095-9203
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3900028
source American Association for the Advancement of Science; JSTOR Archival Journals and Primary Sources Collection; Alma/SFX Local Collection
subjects Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biology
Biomarkers, Pharmacological
Biomarkers, Tumor - genetics
Breast cancer
Cancer
Clinical trials
DNA
Dosing
Drug Design
Drugs
Female
Genetic Markers
Genetic mutation
Genome, Human
Genomics
Germ-Line Mutation
Humans
Molecular Targeted Therapy
Mutations
Neoplasms - drug therapy
Neoplasms - genetics
Oncology
Patients
Pharmaceutical sciences
Pharmacogenetics
REVIEWS
Sequencing
Side effects
Somatic mutation
Tumors
title Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A05%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20Pharmacogenomics:%20Early%20Promise,%20But%20Concerted%20Effort%20Needed&rft.jtitle=Science%20(American%20Association%20for%20the%20Advancement%20of%20Science)&rft.au=McLeod,%20Howard%20L.&rft.date=2013-03-29&rft.volume=339&rft.issue=6127&rft.spage=1563&rft.epage=1566&rft.pages=1563-1566&rft.issn=0036-8075&rft.eissn=1095-9203&rft.coden=SCIEAS&rft_id=info:doi/10.1126/science.1234139&rft_dat=%3Cjstor_pubme%3E41942082%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c575t-fb0a887965b2d76983c6486145cfa7a4178205976158f4cba699a32b672b89f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1321444315&rft_id=info:pmid/23539596&rft_jstor_id=41942082&rfr_iscdi=true